This Article Full Text Full Text (PDF) CME: Take the course for this article: Fertility Preservation in Young Women Undergoing Breast Cancer Therapy eLetters: Submit a response to this article Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services E-mail this article link to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints/Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Sonmezer, M. Articles by Oktay, K. Search for Related Content PubMed PubMed Citation Articles by Sonmezer, M. Articles by Oktay, K.

Breast Cancer

Fertility Preservation in Young Women Undergoing Breast Cancer Therapy

Fertility Preservation Program, Center for Reproductive Medicine and Infertility, Department of Obstetrics and Gynecology, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York, USA

Key Words. Amenorrhea • Breast cancer • Chemotherapy • Fertility preservation

Correspondence: Kutluk Oktay, Fertility Preservation Program, Center for Reproductive Medicine and Infertility, Department of Obstetrics and Gynecology, Joan and Sanford I. Weill Medical College of Cornell University, New York, New York, USA. Telephone: 212-746-4292; Fax: 212-746-5929; e-mail: kuo9001{at}med.cornell.edu; Web site: http://www.ivf.org

Breast cancer accounts for one third of all neoplasms seen in reproductive-age women and affects tens of thousands of women each year in that age group. The adjuvant chemotherapy regimens used for the treatment commonly affect fertility and cause premature ovarian failure. There have been recent advances in the field of fertility preservation, which can allow many of these breast cancer survivors to have children in the future. The most established option is embryo cryopreservation; oocyte cryopreservation can be considered in single women. Both of these approaches require approximately 2 weeks of ovarian stimulation beginning with the onset of the patient’s menstrual cycle. Thus, it is crucial that these patients are referred to appropriate assisted reproduction centers as soon as they are diagnosed with breast cancer. Recently developed ovarian stimulation protocols using tamoxifen and letrozole can be used to increase the margin of safety in these patients. When and if a breast cancer patient does not have time to undergo ovarian stimulation prior to chemotherapy, ovarian cryopreservation for future autotransplantation can be offered as the last resort. The benefit of ovarian protection by gonadotropin-releasing hormone analogues is unproven and unlikely, and thus this treatment should not be offered as the sole method of fertility preservation.

This article has been cited by other articles:

				I. Demeestere, P. Simon, S. Emiliani, A. Delbaere, and Y. Englert Fertility Preservation: Successful Transplantation of Cryopreserved Ovarian Tissue in a Young Patient Previously Treated for Hodgkin's Disease Oncologist, December 1, 2007; 12(12): 1437 - 1442. [Abstract] [Full Text] [PDF]

				Z. Blumenfeld How to Preserve Fertility in Young Women Exposed to Chemotherapy? The Role of GnRH Agonist Cotreatment in Addition to Cryopreservation of Embrya, Oocytes, or Ovaries Oncologist, September 1, 2007; 12(9): 1044 - 1054. [Abstract] [Full Text] [PDF]

				K. Oktay, M. Sonmezer, O. Oktem, K. Fox, G. Emons, and H. Bang Absence of Conclusive Evidence for the Safety and Efficacy of Gonadotropin-Releasing Hormone Analogue Treatment in Protecting Against Chemotherapy-Induced Gonadal Injury Oncologist, September 1, 2007; 12(9): 1055 - 1066. [Abstract] [Full Text] [PDF]